Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Avenzo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
VelaVigo Licenses Nectin4/TROP2 Bispecific Antibody-Drug Conjugate from Avenzo
Details : Avenzo gains an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China).
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Avenzo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?